Enhanced independence: De-biasing processes in psychedelic research and beyond
Katherine Cheung, Rebecca Ehrenkranz, David B. Yaden
Research Ethics April 2, 2025 DOI: 10.1177/17470161251326588 (opens in new tab)
The journal has published a correction to this paper. Read the correction (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Randomized Peer reviewed |
|---|---|
| Keywords | Biasing Independence probability theory Voltage Electrical engineering |
| Citations | 2 |
| Key findings | Four bias mitigation measures—independent data assessment, multisite trials, quantitative bias analysis, and open science practices—are recommended to improve methodological rigor in psychedelic RCTs. |
Abstract
Randomized controlled trials (RCTs) are considered the gold standard for demonstrating the efficacy of a treatment or intervention; however, the RCT study design alone is insufficient to prevent all forms of bias. In this paper, we review conflicts of interest and other biases that pose challenges to the methodological rigor of psychedelic RCTs, and explore recommended bias mitigation measures. We focus on biases of special relevance to psychedelic RCTs and methods of mitigating bias that we believe are actionable and urgent practices to implement in psychedelic research: (1) independent data assessment, (2) multisite trials, (3) quantitative bias analysis, and (4) open science practices. Although we advocate for the adoption of these practices in psychedelic research, they are not psychedelic specific. We suggest that the challenges posed by psychedelic research offer an opportunity for researchers to creatively find and implement solutions across the study lifecycle to reduce bias in other fields of clinical research.
Citations in the library
Cited by 2
- Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal Journal of Affective Disorders September 16, 2025
- Analyzing the concept of independence in psychedelic research. Accountability in research May 1, 2026
Cites 33
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
- Blinding and expectancy confounds in psychedelic randomized controlled trials Expert Review of Clinical Pharmacology May 26, 2021
and 28 more in the library